HG-14OUTCOMES OF CHILDREN WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS TREATED WITH NIMOTUZUMAB® AND IRINOTECAN

Nongnuch Sirachainan,Samart Pakakasama,Usanarat Anurathapan,Ake Hansasuta,Attaporn Boonkerd,Mantana Dhanachai,Noppadol Larbcharoensub,Wipawi Klaisuban,Watinee Sanpote,Surapong Lertthammakiat,Nintita Sripaiboonkij,Apasri Lusawat,Rungrote Natesirinilkul,Suradej Hongeng

HG-14OUTCOMES OF CHILDREN WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS TREATED WITH NIMOTUZUMAB® AND IRINOTECAN

2016

Nongnuch Sirachainan
Samart Pakakasama
Usanarat Anurathapan
Ake Hansasuta
Attaporn Boonkerd
Mantana Dhanachai
Noppadol Larbcharoensub
Wipawi Klaisuban
Watinee Sanpote
Surapong Lertthammakiat
Nintita Sripaiboonkij
Apasri Lusawat
Rungrote Natesirinilkul
Suradej Hongeng

Purpose The outcome of children with high-grade gliomas (HGGs) treated with radiation and adjuvant chemotherapy remains poor. The expression of epidermal growth factor receptor (EGFR) has been established in children with HGGs. This report demonstrated the outcomes of adjuvant nimotuzumab, an EGFR inhibitor, with irinotecan in pediatric HGGs.

Keywords:

Adjuvant
EGFR inhibitors
Nimotuzumab
Chemotherapy
Glioma
Epidermal growth factor receptor
Oncology
Irinotecan
Medicine
Internal medicine
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations